Regulus Therapeutics | RGLS - Ebitda


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Regulus Therapeutics

Regulus Therapeutics reported $-6899000 in EBITDA for its fiscal quarter ending in December of 2022.


Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -135742000 38.56M
AstraZeneca AZN:LN USD 4.28B 965M
Biogen BIIB:US USD 686.7M 312.1M
Celldex Therapeutics CLDX:US USD -31745000 4.53M
Gilead Sciences GILD:US USD 2.24B 456M
GlaxoSmithKline GSK:LN GBP 2.56B 960M
Immunic Inc. VTL:US USD -27219000 2.88M
Incyte Corp INCY:US USD 48.82M 62.76M
Intercept Pharmaceuticals ICPT:US USD -31543000 13.66M
Ionis Pharmaceuticals IONS:US USD -110937000 93.44M
Sangamo BioSciences SGMO:US USD 80.09M 132.14M
Takeda 4502:JP JPY 249.97B 88.8B